- 2012 Charlotte Ng obtained her PhD at the University of Cambridge, UK
- 2012 She began her post-doctoral fellowship at the Institute of Cancer Research, London, UK
- 2013 relocated with the lab to Memorial Sloan-Kettering Cancer Center, New York, US
- 2016-2018 She was a research associate at the University of Basel, Switzerland
- 2019 She started her research group at the University of Bern, Switzerland
- 2023 She joined Humanitas University as an Associate Professor
Charlotte’s work focuses on using multiomics profiling, bioinformatics and computational biology to address outstanding questions and challenges in precision oncology. With many years of experience working with multi-omics data, she is interested in leveraging the abundance of ‘omics’ data derived from clinically annotated samples in computational frameworks to advance our understanding in tumor cellular dynamics, to discover novel biomarkers and therapeutic targets and to elucidate genotype-to-phenotype associations in cancer.
She has developed automated and reproducible sequencing data analysis pipelines, which have been used in 60+ of her own research publications. She is currently active in the International Cancer Genome Consortium (ICGC-ARGO) Data Coordination and Management Working Group, and contributed to European Society for Medical Oncology (ESMO) Translational Research and Personalised Medicine Working Groups and The Cancer Genome Atlas (TCGA) analysis working group. Her current research projects incorporate state-of-the-art single-cell gene expression profiling and spatial transcriptomics to understand tumor cellular composition and dynamics.
- Kashani E, Schnidrig D, Gheinani AH, Ninck MS, Zens P, Maragkou T, Baumgartner U, Schucht P, Rätsch G, Rubin MA, SOCIBP consortium, Berezowska S, Ng CKY, Vassella E. Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors. Neuro-oncol. 25(4):662-673 (2023).
- Ng CKY, Dazert E, Boldanova T, Coto-Llerena M, Nuciforo S, Ercan C, Suslov A, Meier MA, Bock T, Schmidt A, Ketterer S, Wang X, Wieland S, Matter MS, Colombi M, Piscuoglio S, Terracciano LM, Hall MN, Heim MH. Proteogenomic characterization of hepatocellular carcinoma across etiologies and stages. Nature Commun. 13(1):2436 (2022).
- Montazeri H, Coto-Llerena M, Bianco G, Zangene E, Taha-Mehlitz S, Paradiso V, Srivatsa S, de Weck A, Roma G, Lanzafame M, Bolli M, Beerenwinkel N, von Flüe M, Terracciano LM, Piscuoglio S, Ng CKY. Systematic Identification of Novel Cancer Genes through Analysis of Deep shRNA Perturbation Screens. Nucleic Acid Res. 49(15):8488-8504 (2021).
- Bertucci F*, Ng CKY*, Patsouris A*, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F. Genomic characterization of metastatic breast cancers. 569(7757):560–564 (2019).
- Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, Quintavalle C, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM, Piscuoglio S. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol. 29(5):1286–1291 (2018).
